Gland Pharma Limited — Updates, 11-12-2024: Press Release

Gland Pharma Limited has received approval from the US FDA for its Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. This product is bioequivalent to the reference listed drug by Hospira, Inc. and is indicated for treating coagulation disorders caused by vitamin K deficiency. The company anticipates launching the product through its marketing partners soon. According to IQVIA, the product had US sales of approximately USD 15 million for the twelve months ending September 2024. This development reinforces Gland Pharma's position in the injectable pharmaceuticals market and could enhance its revenue streams moving forward. Investors should monitor the upcoming product launch as it presents a potential growth opportunity.